Novel one-step immunoassays to quantify α-synuclein: Applications for biomarker development and high-throughput screening

Journal of Biological Chemistry

Volumn 287, Issue 40, 2012, Pages 33691-33705

  Bidinosti, Michael ^a   Shimshek, Derya R ^a   Mollenhauer, Brit ^b,c   Marcellin, David ^a   Schweizer, Tatjana ^a   Lotz, Gregor P ^a   Schlossmacher, Michael G ^d   Weiss, Andreas ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b PARACELSUS ELENA KLINIK   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL INSIGHT; CELLULAR PATHWAY; DRUG DISCOVERY; GENETIC SCREENS; HIGH-THROUGHPUT SCREENING; HUMAN CEREBROSPINAL FLUID; INHERENT LIMITATIONS; PARKINSON DISEASE; PERFORMANCE PARAMETERS; PROOF OF CONCEPT; RAPID SCREENING; RESONANCE ENERGY TRANSFER; SMALL MOLECULES; STEADY-STATE EXPRESSION; SYNUCLEIN; SYNUCLEIN PROTEINS; THERAPEUTIC TARGETS; TIME-RESOLVED; TR-FRET; WELL PLATES;

CEREBROSPINAL FLUID; ENERGY TRANSFER; GENE THERAPY; MOLECULES; OLIGOMERS; PROTEINS;

ASSAYS;

ALPHA SYNUCLEIN; SMALL INTERFERING RNA;

ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE IDENTIFICATION; GENE LIBRARY; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOASSAY; LIMIT OF DETECTION; MOUSE; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STEADY STATE;

ALPHA-SYNUCLEIN; ANIMALS; ANTIBODIES; BIOCHEMISTRY; BIOLOGICAL MARKERS; COHORT STUDIES; DRUG DESIGN; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION REGULATION; GENE LIBRARY; HUMANS; IMMUNOASSAY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; RNA, SMALL INTERFERING;

EID: 84866904835     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.379792     Document Type: Article

References (48)

1. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) α-Synuclein in Lewy bodies. Nature 388, 839-840
2. Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., Cao, S., Caldwell, K. A., Caldwell, G. A., Marsischky, G., Kolodner, R. D., Labaer, J., Rochet, J. C., Bonini, N. M., and Lindquist, S. (2006) α-Synuclein blocks ER-Golgi traffic, and Rab1 rescues neuron loss in Parkinson models. Science 313, 324-328 (Pubitemid 44480951)
3. Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., Chaudhry, F. A., Nicoll, R. A., and Edwards, R. H. (2010) Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66-79
4. Thayanidhi, N., Helm, J. R., Nycz, D. C., Bentley, M., Liang, Y., and Hay, J. C. (2010) α-Synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 21, 1850-1863
5. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) α-Synuclein locus triplication causes Parkinson disease. Science 302, 841 (Pubitemid 37339619)
6. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., Waucquier, N., Defebvre, L., Amouyel, P., Farrer, M., and Destée, A. (2004) α-Synuclein locus duplication as a cause of familial Parkinson disease. Lancet 364, 1167-1169 (Pubitemid 39296604)
7. Cronin, K. D., Ge, D., Manninger, P., Linnertz, C., Rossoshek, A., Orrison, B. M., Bernard, D. J., El-Agnaf, O. M., Schlossmacher, M. G., Nussbaum, R. L., and Chiba-Falek, O. (2009) Expansion of the Parkinson disease-associated SNCA-Rep1 allele up-regulates human α-synuclein in transgenic mouse brain. Hum. Mol. Genet. 18, 3274-3285
8. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson disease. Science 276, 2045-2047 (Pubitemid 27443610)
9. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schöls, L., and Riess, O. (1998) A30P mutation in the gene encoding α-synuclein in Parkinson disease. Nat. Genet. 18, 106-108
10. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Muñoz, D. G., and de Yebenes, J. G. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173 (Pubitemid 38166992)
11. Cullen, V., Sardi, S. P., Ng, J., Xu, Y. H., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., Rochet, J. C., Glicksman, M. A., Cheng, S. H., Grabowski, G. A., Shihabuddin, L. S., and Schlossmacher, M. G. (2011) Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69, 940-953
12. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., 3rd, and Shen, J. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U.S.A. 107, 9879-9884
13. Mazzulli, J. R., Xu, Y. H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., and Krainc, D. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52
14. Tomlinson, J. J., Cullen, V., Schlossmacher, M. G. (2010) in Protein Misfolding Diseases: Current and Emerging Principles and Therapies (Ramirez-Alvaro, M., Kelly, J. W., and Dobson, C. M., eds.) pp. 817-844, John Wiley & Sons, Inc., New York
15. Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., Trenkwalder, C., Sarracino, D. A., Vonsattel, J. P., Locascio, J. J., El-Agnaf, O. M., and Schlossmacher, M. G. (2008) Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315-325
16. Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., and Schlossmacher, M. G. (2011) α-Synuclein andτ concentrations in cerebrospinal fluid of patients presenting with parkinsonism. A cohort study. Lancet Neurol. 10, 230-240
17. Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., Montine, T. J., Hancock, A. M., Hwang, H., Pan, C., Bradner, J., Kang, U. J., Jensen, P. H., and Zhang, J. (2010) DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson disease. Brain 133, 713-726
18. Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., and El-Agnaf, O. M. (2006) Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson disease. Biochem. Biophys. Res. Commun. 349, 162-166 (Pubitemid 44331776)
19. Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., and El-Agnaf, O. M. (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766-1772
20. Ohrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., and Zetterberg, H. (2009) Cerebrospinal fluid α-synuclein in neurodegenerative disorders. A marker of synapse loss? Neurosci. Lett. 450, 332-335
21. Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., De Carlo, C., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., Tambasco, N., Eusebi, P., Rossi, A., Onofrj, M., Padovani, A., Calabresi, P., and El-Agnaf, O. (2011) Cerebrospinal fluid τ/α-synuclein ratio in Parkinson disease and degenerative dementias. Mov. Disord. 26, 1428-1435
22. Spies, P. E., Melis, R. J., Sjögren, M. J., Rikkert, M. G., and Verbeek, M. M. (2009) Cerebrospinal fluid α-synuclein does not discriminate between dementia disorders. J. Alzheimers Dis. 16, 363-369
23. Noguchi-Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono, K., Nakagawa, M., El-Agnaf, O. M., and Yamada, M. (2009) CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer disease. Brain Res. 1251, 1-6
24. Kasuga, K., Tokutake, T., Ishikawa, A., Uchiyama, T., Tokuda, T., Onodera, O., Nishizawa, M., and Ikeuchi, T. (2010) Differential levels of α-synuclein, β-amyloid42 and τ in CSF between patients with dementia with Lewy bodies and Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 81, 608-610
25. Montine, T. J. (2011) Parkinson disease. PD biomarkers-use of α-synuclein reaches new levels. Nat. Rev. Neurol. 7, 308-309
26. Mollenhauer, B., El-Agnaf, O. M., Marcus, K., Trenkwalder, C., and Schlossmacher, M. G. (2010) Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate. Review of the literature and considerations for future studies. Biomark Med. 4, 683-699
27. van der Putten, H., Wiederhold, K. H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P., Ruegg, M. A., Lin, S., Caroni, P., Sommer, B., Tolnay, M., and Bilbe, G. (2000) Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20, 6021-6029 (Pubitemid 30658395)
28. Rieker, C., Dev, K. K., Lehnhoff, K., Barbieri, S., Ksiazek, I., Kauffmann, S., Danner, S., Schell, H., Boden, C., Ruegg, M. A., Kahle, P. J., van der Putten, H., and Shimshek, D. R. (2011) Neuropathology in mice expressing mouse α-synuclein. PLoS One 6, e24834
29. Armbruster, D. A., and Pry, T. (2008) Limit of blank, limit of detection, and limit of quantitation. Clin. Biochem. Rev. 29, S49-S52
30. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67-73 (Pubitemid 29278954)
31. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., and Lansbury, P. T., Jr. (2002) α-Synuclein, especially the Parkinson disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102 (Pubitemid 35266514)
32. Miake, H., Mizusawa, H., Iwatsubo, T., and Hasegawa, M. (2002) Biochemical characterization of the core structure of α-synuclein filaments. J. Biol. Chem. 277, 19213-19219 (Pubitemid 34952489)
33. El-Agnaf, O. M., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., and Allsop, D. (2006) Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson disease. FASEB J. 20, 419-425 (Pubitemid 44933318)
34. Park, M. J., Cheon, S. M., Bae, H. R., Kim, S. H., and Kim, J. W. (2011) Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson disease. J. Clin. Neurol. 7, 215-222
35. Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., and Rubinsztein, D. C. (2003) α-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009-25013 (Pubitemid 37548663)
36. Leng, Y., and Chuang, D. M. (2006) Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 26, 7502-7512 (Pubitemid 44315219)
37. Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B. M., Schjeide, L. M., Meissner, E., Zauft, U., Allen, N. C., Liu, T., Schilling, M., Anderson, K. J., Beecham, G., Berg, D., Biernacka, J. M., Brice, A., DeStefano, A. L., Do, C. B., Eriksson, N., Factor, S. A., Farrer, M. J., Foroud, T., Gasser, T., Hamza, T., Hardy, J. A., Heutink, P., Hill-Burns, E. M., Klein, C., Latourelle, J. C., Maraganore, D. M., Martin, E. R., Martinez, M., Myers, R. H., Nalls, M. A., Pankratz, N., Payami, H., Satake, W., Scott, W. K., Sharma, M., Singleton, A. B., Stefansson, K., Toda, T., Tung, J. Y., Vance, J., Wood, N. W., Zabetian, C. P., Young, P., Tanzi, R. E., Khoury, M. J., Zipp, F., Lehrach, H., Ioannidis, J. P., and Bertram, L. (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson disease genetics. The PDGene database. PLoS Genet 8, e1002548
38. Pankratz, N., Beecham, G. W., DeStefano, A. L., Dawson, T. M., Doheny, K. F., Factor, S. A., Hamza, T. H., Hung, A. Y., Hyman, B. T., Ivinson, A. J., Krainc, D., Latourelle, J. C., Clark, L. N., Marder, K., Martin, E. R., Mayeux, R., Ross, O. A., Scherzer, C. R., Simon, D. K., Tanner, C., Vance, J. M., Wszolek, Z. K., Zabetian, C. P., Myers, R. H., Payami, H., Scott, W. K., and Foroud, T. (2012) Meta-analysis of Parkinson disease. Identification of a novel locus, RIT2. Ann. Neurol. 71, 370-384
39. Pankratz, N., Wilk, J. B., Latourelle, J. C., DeStefano, A. L., Halter, C., Pugh, E. W., Doheny, K. F., Gusella, J. F., Nichols, W. C., Foroud, T., and Myers, R. H. (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124, 593-605
40. Simón-Sánchez, J., van Hilten, J. J., van de Warrenburg, B., Post, B., Berendse, H. W., Arepalli, S., Hernandez, D. G., de Bie, R. M., Velseboer, D., Scheffer, H., Bloem, B., van Dijk, K. D., Rivadeneira, F., Hofman, A., Uitterlinden, A. G., Rizzu, P., Bochdanovits, Z., Singleton, A. B., and Heutink, P. (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. Eur. J. Hum. Genet. 19, 655-661
41. Wang, Y., Shi, M., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M., Siderowf, A. D., Hurtig, H., Litvan, I., Schiess, M. C., Peskind, E. R., Masuda, M., Hasegawa, M., Lin, X., Pan, C., Galasko, D., Goldstein, D. S., Jensen, P. H., Yang, H., Cain, K. C., and Zhang, J. (2012) Phosphorylated α-synuclein in Parkinson disease. Sci. Transl. Med. 4, 121ra120
42. Lindersson, E., Beedholm, R., Højrup, P., Moos, T., Gai, W., Hendil, K. B., and Jensen, P. H. (2004) Proteasomal inhibition by α-synuclein filaments and oligomers. J. Biol. Chem. 279, 12924-12934 (Pubitemid 38445867)
43. Paleologou, K. E., Kragh, C. L., Mann, D. M., Salem, S. A., Al-Shami, R., Allsop, D., Hassan, A. H., Jensen, P. H., and El-Agnaf, O. M. (2009) Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132, 1093-1101
44. Crotty, T., Cai, J., Sakane, F., Taketomi, A., Prescott, S. M., and Topham, M. K. (2006) Diacylglycerol kinase δ regulates protein kinase C and epidermal growth factor receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 103, 15485-15490 (Pubitemid 44625618)
45. Mérida, I., Avila-Flores, A., and Merino, E. (2008) Diacylglycerol kinases. At the hub of cell signaling. Biochem. J. 409, 1-18
46. Houssa, B., de Widt, J., Kranenburg, O., Moolenaar, W. H., and van Blitterswijk, W. J. (1999) Diacylglycerol kinase θ binds to and is negatively regulated by active RhoA. J. Biol. Chem. 274, 6820-6822
47. Scherzer, C. R., Grass, J. A., Liao, Z., Pepivani, I., Zheng, B., Eklund, A. C., Ney, P. A., Ng, J., McGoldrick, M., Mollenhauer, B., Bresnick, E. H., and Schlossmacher, M. G. (2008) GATA transcription factors directly regulate the Parkinson disease-linked gene α-synuclein. Proc. Natl. Acad. Sci. U.S.A. 105, 10907-10912
48. Zhou, Z., Kim, J., Insolera, R., Peng, X., Fink, D. J., and Mata, M. (2011) Rho GTPase regulation of α-synuclein and VMAT2. Implications for pathogenesis of Parkinson disease. Mol. Cell Neurosci. 48, 29-37